By interrupting the CCR2–CCL2 axis and by blocking monocyte migration, these trials have provided more insights into the tumor microenvironment and indicated a direct mechanism by which these therapeutic agents could work in human OSA patients. The gene discussed is CCR2; the disease is obstructive sleep apnea syndrome.